This document provides practical wisdom from an author with over 30 years of psychiatric clinical trial experience, distilled into concrete strategies you can implement immediately.

Baseline inflation poses a major threat to CNS trial integrity by constraining the measurable range of improvement and obscuring true treatment effects.

This is Part 1 of a 3-part series demonstrating how robust data analytics can address the real-world implications of data quality issues that affect patients waiting for effective treatments.

Discover the transformation of a complex assessment challenge into a competitive advantage. Our electronic CDRS-R doesn't just digitize the scale—it embeds clinical expertise, automates quality controls, and guides raters through every step to ensure consistent, reliable data.

The future of psychedelic medicine depends on applying strict scientific standards, using evidence-based approaches to manage the inherent challenges of studying these consciousness-altering compounds.

In a Phase 3 psychiatry trial, a pharmaceutical company partnered with Signant to revolutionize patient recruitment through data-driven site selection using PureSignal Analytics.

A pharma company used Signant Health's RTSM solution in a Phase 2 schizophrenia trial to ensure drug availability, maintain study balance, prevent duplicate allocations, and manage returns and destruction of unused drugs.

Signant Biotech optimized technology for an emerging biopharmaceutical's Phase 2 COVID treatment trial in critically ill patients, minimizing paper data risks and streamlining consent and data management across multiple sites and solutions.

A Japan-based biotechnology company leveraged Signant SmartSignals® GxP Inventory, which improved visibility, reduced risks and costs, and optimized operations in this case study.

Signant’s SmartSignals® RTSM solution helped an innovative biopharmaceutical company secure an FDA Orphan Drug designation for its cardiomyopathy drug.